$Pacific Biosciences of California(PACB)$ ARK Investment Management has been significantly increased its stake in Pacific Biosciences (PACB) in late 2025 and early 2026, signaling a strong, continued conviction in the genomics company despite weak market sentiment and financial challenges.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
